These observations confirmed that aberrant IFNR signaling is one of the essential factors in the context of the NLRP12-derived pathogenesis of lupus, and blockade of IFNAR might be a potential strategy for the treatment of SLE patients with intrinsically low NLRP12 expression. This evidence concerns the gene IFNAR1 and systemic lupus erythematosus.